The Bhatia group reported the use of a “tandem peptide “construct containing the myristoylated transportan fused to a PEG spacer with a C-terminal targeting peptide, iRGD (cyclic peptide of CRGDKGPDC), for pancreatic tumor delivery of anti-KRAS (WT) siRNA [158]. This evidence concerns the gene KRAS and pancreatic neoplasm.